Business Wire

CA-BEHAVIOSEC

29.7.2021 09:02:06 CEST | Business Wire | Press release

Share
BehavioSec Expands Portfolio and Opens Market Access with Another Industry First

BehavioSec , industry pioneer and technology leader for behavioral biometrics and continuous authentication, today announced that it has extended its patented technology and BehavioSense platform into a SOC/ISO compliant, hosted-version and a cloud-native, SaaS version. These new versions will help more organizations meet compliance and cloud mandates, support frictionless multi-factor authentication (MFA), and gain access to the market’s most advanced behavioral biometrics technology – which until now – has only been employed within the world’s largest banks, e-Identity providers, and online retailers.

According to the recent July release of the 2021 Gartner ® Market Guide for Online Fraud Detection , “The convergence between online fraud detection (OFD), identity proofing and authentication continues with many organizations applying OFD capabilities to mitigate risk in identity proofing and authentication events.” The report further adds, “Banks are becoming increasingly comfortable with using vendor-hosted or SaaS solutions from vendors for transaction monitoring, which is a OFD capability that has traditionally been deployed on-premises in banking environments.” 1

As biometrics technology adoption increases and more companies look to hosted and SaaS-based solutions, the new SaaS-version of the company’s BehavioSense platform is the market’s first to offer comprehensive behavioral biometrics for MFA in this lightweight, self-service form factor. Unlike other SaaS-based solutions that may specialize in just web interfaces or typing, this new platform brings the company’s deep insights across device types and human interaction to identify unique humans during the authentication process.

“As more organizations move through digital transformation projects, adopting solutions that can offer accuracy, protect privacy, reduce friction – and be agile – is critical,” said Ed Amoroso, Founder and CEO of analyst firm TAG CYBER and former Chief Security Officer at AT&T. “This is especially important for organizations with continuous delivery models for their online services or those concerned with insider threat in our current remote/hybrid work environments.”

The new SaaS packaging is more than a port – it is purpose-built to streamline the BehavioSec API and feature set to offer transparent and passwordless MFA, reduction of step-ups, and replacement of legacy technologies like knowledge-based challenges. In particular, while the new service may seamlessly work in conjunction with one-time passwords (OTP), it can also serve as the means to retire OTP – as OTPs and SMS codes are notorious for their added costs to both business and consumer, friction-full experiences, and recently – vulnerability to a rising trend of SMS fraud .

To ensure rapid time-to-value, the new SaaS solution offers an especially lightweight SDK for easy deployment and integration with Identity & Access Management (IAM) platforms already implemented within customer environments for business, consumer, or workforce protection.

“The vision at the outset of this project was to bring this powerful technology used by the largest financial institutions to a broader audience needing a solution for digital identity protection that supports both compliance and privacy protection, ” said BehavioSec VP of Products, Jordan Blake. “And it is not enough to make it available. It has to be highly deployable and user friendly, too - offering high value.”

In addition to the new SaaS version, the commercial release of the vendor-hosted BehavioSense service offers sophisticated fraud organizations the full breadth and depth of BehavioSec fraud prevention technology in a Type 2 SOC 2 and ISO 27001 compliant environment. While the company’s software-based BehavioSense platform has always been fully cloud-compatible for deployment within customer environments (including public cloud), this release comes after the company’s April announcement of Type 1 SOC 2 certification and the subsequent completion of the full Type 2 and ISO requirements.

Today’s announcement follows the company’s 2020 performance that saw a successful 300% growth and a series of developments during the first half of 2021, including significant platform updates and recently, key patent grants . As the company continues to invest in technology innovation and expansion of its go-to-market capabilities, the tripling of its platform footprint into a portfolio play provides a foundation to offer customers greater flexibility with multiple packaging and licensing options tightly aligned to customer requirements and phased implementations.

The new BehavioSense SaaS platform is available now in controlled release with general availability slated for later this year. A free version of the product offering immediate access for developers may be requested online on the BehavioSec website. Customers interested in free, full production trials of any of the company’s solutions may contact the BehavioSec sales team at sales@behaviosec.com . For more information on these new solutions, visit www.behaviosec.com/platform .

1 Gartner, “Market Guide for Online Fraud Detection” Akif Khan, Jonathan Care, 12 July 2021

GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.

About BehavioSec

BehavioSec is the industry pioneer and technology leader for behavioral biometrics and continuous authentication, safeguarding millions of users and billions of transactions today. Deployed across Global 2000 companies to dramatically reduce fraud, friction, threat, and theft, BehavioSec verifies and protects human digital identities by understanding how we uniquely type and swipe across our ever-changing devices. Whether used in the Cloud or on-premises, BehavioSec delivers the superior user experience, precision, and scale needed by organizations to keep customers engaged while catching evasive, real-time attacks other solutions miss.

Founded in the Nordics in 2008 out of groundbreaking research, industry-recognized BehavioSec partners with market leaders and organizations like DARPA, and has earned investment from top investment firms like Forgepoint Capital, Cisco, ABN AMRO, Conor Ventures, and Octopus Ventures. Headquartered in San Francisco, CA with offices worldwide, BehavioSec is ready to help you reduce risk, improve compliance, and digitally transform your distributed workforce and customer experience. www.behaviosec.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye